The Effect of Metabolic Syndrome on Prostate-specific Antigen Levels: A Meta-analysis

Harris L. Lim; Sigfred Ian R. Alpajaro; Leonardo Arriola Zabala III; Lizlane Roman Zamora; Janine Mae Elaine Kua Zapata

Vol. 31 No. 1 (2021), Original Research

Vol. 31 No. 1 (2021)

The Effect of Metabolic Syndrome on Prostate-specific Antigen Levels: A Meta-analysis

Original Research

Published 2022-01-25

Harris L. Lim, MD⁺⁻
Sigfred Ian R. Alpajaro, MD⁺⁻
Leonardo Arriola Zabala III, MD⁺⁻
Lizlane Roman Zamora, MD⁺⁻
Janine Mae Elaine Kua Zapata, MD⁺⁻

Harris L. Lim, MD

Section of Urology, Department of Surgery, University of Santo Tomas Hospital

Sigfred Ian R. Alpajaro, MD

Section of Urology, Department of Surgery, University of Santo Tomas Hospital

Leonardo Arriola Zabala III, MD

Section of Urology, Department of Surgery, University of Santo Tomas Hospital

Lizlane Roman Zamora, MD

Section of Urology, Department of Surgery, University of Santo Tomas Hospital

Janine Mae Elaine Kua Zapata, MD

Section of Urology, Department of Surgery, University of Santo Tomas Hospital

PDF

Keywords

prostate cancer
prostate-serum antigen
prostate cancer screening (non-MeSH)
metabolic syndrome

How to Cite

Lim, H. L., Alpajaro, S. I. R., Zabala III, L. A., Zamora, L. R., & Zapata, J. M. E. K. (2022). The Effect of Metabolic Syndrome on Prostate-specific Antigen Levels: A Meta-analysis. Philippine Journal of Urology, 31(1). Retrieved from https://pjuonline.com/index.php/pju/article/view/125

Abstract

It has been proposed that Metabolic Syndrome causes an inadvertent lowering of PSA levels in affected individuals.

Objective: This study aimed to determine the effect of metabolic syndrome on the serum PSA level.

Methods: Literature search was done using MEDLINE and Cochrane databases. The primary outcome measure was serum prostate-specific antigen (PSA) levels. Secondary outcome measures included prostate volume, plasma volume, and PSA mass density. Mean differences were computed using Review Manager 5.3 software.

Results: There were six articles available for analysis with a total of 33,775 in metabolic syndrome group (MS) and 70,305 in non-metabolic syndrome group (NM). Overall, there was no significant difference between the PSA levels between MS and NM group. The prostate and plasma volume were significantly higher in the MS compared with NM, having mean difference of 2.95 mL (95% CI, 1.41 to 4.49) and 162.68 mL (95% CI, 120.24 to 205.11), respectively. However, there were no significant difference in the PSA mass density between metabolic and non-metabolic syndrome.

Conclusion: Metabolic syndrome does not affect PSA levels and PSA mass density, despite increase in hemodilution.

PDF